Home » Healthcare » Type 2 Diabetes Market

Type 2 Diabetes Market By Blood Glucose Monitoring (Blood Glucose Meters, Continuous Glucose Monitoring (CGM) Systems, Lancets and Lancing Devices) By End User (Hospitals, Clinics and Specialty Centers, Retail Pharmacies, Home Use) By Complications Management (Diabetic Neuropathy, Diabetic Nephropathy, Diabetic Retinopathy, Cardiovascular Complications)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Market Insights

The global demand for type 2 diabetes was valued at USD 29945.8 Million in 2022 and is expected to reach USD 58798.6 Million in 2030, growing at a CAGR of 8.8% between 2023 and 2030.
The insulin therapy segment is the market leader in medications and therapies, accounting for more than 20% of total value in 2022, while the combination therapies segment is anticipated to grow rapidly over the projection period.
The diabetic nephropathy management category is expected to expand quickly in the forecast period, while the diabetic neuropathy segment has the greatest market share in 2022.
Continuous glucose monitoring (CGM) systems dominate the global need for type 2 diabetes, accounting for more than 40% in 2022 and are predicted to expand at a high CAGR.
The hospital’s category dominated the market with 30% of the total revenue share by end users. In contrast, the clinics and specialty centers segment will expand fastest over the projected time frame.
The adult category dominated the market with 60% of the total revenue share by age group segment.
North America is propelling the growth of the type 2 diabetes industry, accounting for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe held more than 20% of the market.
Type 2 diabetes continues to be a global health concern, with a growing prevalence linked to factors like unhealthy diets, sedentary lifestyles, and obesity.
The market has witnessed ongoing R&D of innovative medications, including GLP-1 receptor agonists and SGLT-2 inhibitors, which offer new treatment options beyond traditional oral medications and insulin.
Emerging lifestyle interventions, including weight management programs and exercise regimes, have gained global prominence as complementary approaches to managing type 2 diabetes.

Executive Summary

Market Definition

The type 2 diabetes market encompasses the entire ecosystem dedicated to addressing the prevention, diagnosis, treatment, and management of type 2 diabetes mellitus. Pharmaceutical firms, producers of medical devices, healthcare organisations, insurers, researchers, and governmental organisations all collaborate to provide a wide range of goods and services aimed at assisting people with type 2 diabetes in controlling their blood sugar levels, minimising complications, and improving their general well-being. It includes pharmaceuticals, insulin delivery devices, digital health solutions, lifestyle interventions, patient education programs, and regulatory frameworks, all aimed at improving patient outcomes, reducing healthcare costs, and managing the chronic nature of type 2 diabetes.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global type 2 diabetes market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 8.8% between 2023 and 2030. The market was valued at USD 29945.8 million in 2022 and is expected to reach USD 58798.6 million in 2030.

Diabetes drugs are medications used to treat type 1 & type 2 diabetes by reducing the body’s blood glucose level. Diabetes is treated with various groups of drugs that are delivered orally, intravenously, and subcutaneously. The increased prevalence of diabetes, particularly type-2 diabetes, and a growing need for effective diabetic drug therapy are some of the factors expected to contribute to the diabetes medications market growth throughout the forecast duration.

Type 2 diabetes is a prevalent metabolic illness that is closely linked to obesity and metabolic problems. According to the National Centre for Biotechnology Information, there were 89 million cases of type 2 diabetes in 2014, with 380 million cases expected by 2024. As a result, the rising global prevalence of diabetes is propelling the type 2 diabetes market forward.

Governments all over the world are working continuously to develop the type 2 diabetes sector. Government agencies are cooperating with leading industry players to offer new products in the global type 2 diabetes market. Market players are not only releasing novel pharmaceuticals and therapies but also technologies and instruments for the treatment and diagnosis of type 2 diabetes. In addition, governments in developing countries provide tax benefits, such as tax incentives and subsidies, to the companies that make treatments and medications for type 2 diabetes.

Segmentation by Medications and Therapies

The combination therapies segment will exhibit the highest CAGR in the projected period. The increasing trend of combining multiple medications for more effective glycemic control is driving this segment’s growth.
Insulin therapy currently dominates the market share, accounting for over 20% in 2022. This segment’s leadership is attributed to its established role in diabetes management, especially for patients with advanced disease stages or insulin resistance.

Segmentation by Blood Glucose Monitoring

The lancets and lancing devices segment is expected to witness the highest CAGR in the forecasted period. This growth is fueled by the emphasis on painless and minimally invasive blood glucose monitoring techniques.
Continuous glucose monitoring (CGM) systems hold the majority of the market share, commanding over 40% in 2022. The demand for real-time, continuous monitoring to improve glycemic control is driving the dominance of this segment.

Segmentation by End User

Hospitals dominate the end-user category, accounting for more than 30% of the global demand for type 2 diabetes management in 2022. Their pivotal role in managing acute diabetes-related complications and providing specialized care contributes to this strong market presence.
Clinics and specialty centers fulfill the remaining need for type 2 diabetes management. These facilities play a key role in routine diabetes care, patient education, and long-term management.

Segmentation by Complications Management

Diabetic neuropathy emerges as the leading category in type 2 diabetes applications, capturing a substantial 34% share in 2022. The high prevalence of neuropathic symptoms and the need for effective pain management drive the prominence of this segment.
The diabetic nephropathy and retinopathy segments are expected to experience rapid growth over the coming years, reflecting the increasing focus on preventing and managing kidney and eye complications associated with type 2 diabetes.

Segmentation by Age Group

The pediatric segment is projected to exhibit the highest CAGR in the projection period, underscoring the growing concern about early-onset diabetes in children and adolescents.
The adult segment currently leads the market share, accounting for over 60% in 2022. The majority of type 2 diabetes cases occur in adults, particularly in middle-aged and older populations.

Segmentation by Region

North America stands as a highly profitable region for industry players in the type 2 diabetes market, with a dominant share of over one-third in 2022. This market’s strength is attributed to advanced healthcare infrastructure, higher disease prevalence, and robust R&D activities.
Asia Pacific and Europe collectively represent just under 54% of the market share in 2022. Europe, with a share of over 20% in the same year, demonstrates a strong market presence owing to a well-established healthcare system.
The rest of the world, including Latin America, the Middle East, and Africa, contributes to the remaining demand for type 2 diabetes management, with untapped potential for growth. Emerging economies in these regions are witnessing an increase in diabetes cases due to changing lifestyles and are thus becoming essential markets for future expansion.

North America led the type 2 diabetes market in 2022, accounting for 35% of global revenue. North America, particularly the United States, has one of the greatest prevalence rates of type 2 diabetes globally. Around 37 million Americans have diabetes, with type 2 diabetes accounting for 90–95% of cases, according to the Centres for Disease Control & Prevention. Type 2 diabetes mainly impacts people over the age of 45, while it is increasingly impacting teenagers, adolescents, and young adults. This high disease burden has driven the demand for diabetes-related products and services, making it a leading global market. North America also has a high level of healthcare spending, with a substantial portion allocated to diabetes management. This investment in healthcare has driven the market’s growth and innovation.

Over the projection period, Asia Pacific is expected to be the fastest-growing region in the global type 2 diabetes market due to several key factors. This region is home to a substantial percentage of the world’s population, with countries like China and India having the largest populations. As a result, even a moderate increase in the prevalence of type 2 diabetes translates into a substantial patient base and market potential. Rapid urbanization in the region has led to lifestyle changes, including decreased physical activity and the adoption of Western diets, contributing to the rise in type 2 diabetes cases. Many countries in the Asia Pacific are also experiencing robust economic growth, which is improving access to healthcare services and increasing disposable income. This, in turn, is driving demand for advanced diabetes management solutions.

Key Highlights of the Report

The global type 2 diabetes market is segmented by medications and therapies, blood glucose monitoring, end user, complications management, age group, and region. Combination therapies are emerging as a high-growth segment, driven by their effectiveness in glycemic control and improved patient outcomes. The trend towards combining multiple medications continues to gain momentum. CGM systems dominate the blood glucose monitoring segment, providing real-time data for better glycemic control. The demand for continuous and convenient monitoring solutions remains robust. Hospitals play a leading role in type 2 diabetes management, addressing acute complications and providing specialized care. Their role is expected to continue growing at a high rate. The pediatric segment is projected to exhibit significant growth, highlighting the concern regarding early-onset diabetes in children and adolescents.

The global type 2 diabetes market is mainly driven by the persistent increase in diabetes prevalence due to lifestyle factors, rising awareness, and the imperative need for effective prevention and management solutions. Ongoing pharmaceutical & technological innovations, particularly in combination therapies, insulin delivery systems, and digital health technologies, are propelling market growth. Additionally, the aging global population, government initiatives to combat diabetes, and the expansion of healthcare infrastructure contribute significantly to the market’s development. However, the market faces challenges such as high healthcare costs, disparities in access to care, the burden of comorbid conditions, regulatory complexities, and the demand for more personalized treatment approaches, making it a complex landscape to navigate.

North America stands as the dominant regional market in the global type 2 diabetes landscape, commanding a significant share of market revenue. The region benefits from well-established healthcare infrastructure, a high prevalence of type 2 diabetes, and robust R&D activities. Supportive government initiatives and substantial investments in diabetes management further drive regional market growth. Meanwhile, Asia Pacific is positioned to exhibit the highest CAGR over the estimated period. The regional pharmaceutical sector has seen rapid expansion, particularly in India and China, contributing to its growing prominence. Japan, with its substantial senior population, plays a pivotal role in driving product acceptance and innovation in the Asia Pacific region.

What Are The Main Drivers Of The Global Type 2 Diabetes Market?

The main drivers of the global type 2 diabetes market are the continuously rising prevalence of type 2 diabetes due to lifestyle factors like poor diets and sedentary habits, increasing awareness of the condition, and the urgent need for effective prevention and management solutions. Additionally, ongoing research & development efforts, particularly in the areas of innovative medications, advanced insulin delivery systems, and digital health technologies, are driving market growth. Moreover, the aging global population and the associated higher risk of diabetes, as well as government initiatives to address the diabetes epidemic and improve healthcare infrastructure, contribute significantly to the expansion of the type 2 diabetes market.

What Are The Major Challenges Faced By The Global Type 2 Diabetes Market?

The global type 2 diabetes market faces several major challenges, including the escalating healthcare costs associated with diabetes management and complications, especially in aging populations. Besides, there is a need for improved access to diabetes care and medications, particularly in low- and middle-income countries. The market must also address the rising concerns of treatment affordability and disparities in healthcare access. Furthermore, the increasing prevalence of comorbid conditions, such as obesity and cardiovascular disease, complicates diabetes management. Regulatory hurdles, drug pricing pressures, and the demand for more personalized treatment approaches add to the complexity of the market.

What Are The Growth Opportunities In The Global Type 2 Diabetes Market?

The global type 2 diabetes market presents growth opportunities driven by several factors, including the increasing global prevalence of type 2 diabetes, particularly in emerging markets, which offers potential for market expansion. Innovations in pharmaceuticals, insulin delivery systems, and continuous glucose monitoring devices provide opportunities for developing and marketing new, more effective treatments. Furthermore, the adoption of digital health solutions, telemedicine, and data analytics for diabetes management offers avenues for technology-driven growth. Lifestyle interventions, preventive programs, and patient education initiatives represent areas where targeted efforts can lead to reduced incidence and better outcomes, creating room for growth.

Market Drivers

Several factors drive the global type 2 diabetes market. The following are the key drivers of the global type 2 diabetes market:

Rising Diabetes Prevalence

Growing diabetes incidence, sedentary lifestyles, and numerous other chronic conditions, such as hypertension, primarily drive the global type 2 diabetes market growth. The International Diabetes Federation (IDF) estimates that around 537 million adults (20-79 years old) have diabetes, with the number of diabetic patients anticipated to climb to 643 million by 2030 and 783 million by 2045. As more individuals are diagnosed with type 2 diabetes, there is an expanding demand for products and services related to its management and treatment. The increase in prevalence has also led to greater awareness of the disease among both healthcare providers and the general population, prompting earlier diagnosis and intervention.

Diabetes can also be inherited, and it is linked to a patient’s family history and genetics. Although not everyone inherits it, persons with a family history are more inclined to get diabetes. Besides, increased public awareness of diabetes self-management supports market expansion. Furthermore, the growth in diabetes-causing parameters like family history, lifestyle choices, food, obesity, and geography propels the market forward. Obesity is a substantial risk factor for diabetes development. According to the World Population Review, 36.2% of the adult population in the United States will be obese by the end of 2023. Diabetes is also caused by environmental factors such as dirty air, water, and soil, a lack of vitamin D, enterovirus exposure, and immune cell destruction.

Market Restraints

The global type 2 diabetes market faces challenges that may hinder its growth. These include the following:

High Healthcare Costs

One of the primary restraints on the global type 2 diabetes market is the higher cost associated with diabetes care and management. This includes the expense of medications, insulin, monitoring devices, regular check-ups, and potential hospitalizations for complications. The financial burden of managing diabetes can be particularly challenging for patients without adequate health insurance or in regions with limited access to affordable healthcare services. Additionally, the cost of newer, more advanced medications and technologies, while offering improved outcomes, can be prohibitive for some patients and healthcare systems. High healthcare costs can result in delayed or inadequate treatment, leading to poorer health outcomes and an increased risk of diabetes-related complications.

Opportunities

The global type 2 diabetes market offers significant growth opportunities. These include the following:

Emerging Digital Health and Telemedicine Solutions

The robust growth of digital health technologies and telemedicine presents a major opportunity in the type 2 diabetes industry. These technologies offer innovative ways to deliver diabetes care, monitor patients remotely, and provide real-time support and education. Digital health solutions include smartphone apps for glucose monitoring, wearable devices for continuous glucose monitoring (CGM), and telemedicine platforms for remote consultations with healthcare providers. These technologies not only improve patient engagement and convenience but also enable healthcare professionals to collect and analyze vast amounts of data for better decision-making. With the increasing adoption of digital health and telemedicine, patients with type 2 diabetes can access care more easily, receive timely interventions, and benefit from ongoing remote monitoring, potentially leading to improved glycemic control and reduced healthcare costs.

Competitive Landscape

Key Players

The worldwide type 2 diabetes market is extremely competitive and characterized by the existence of several pharmaceutical firms, medical device makers, and healthcare service providers. The following are some of the top market players and their market shares:

Amgen Inc
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co. Ltd
Eli Lilly and Co.
Merck & Co. Inc
Novartis AG
Novo Nordisk AS
Sanofi SA
Takeda Pharmaceutical Co. Ltd
Others

These market players focus on developing and marketing a wide range of diabetes medications, insulin delivery systems, and digital health solutions to gain a competitive edge. Besides, partnerships and collaborations between pharmaceutical firms, technology companies, and healthcare providers are becoming increasingly common, aiming to offer integrated solutions that encompass medication, monitoring, and patient support.

The competitive landscape is also influenced by regulatory dynamics, pricing pressures, and evolving healthcare policies, which shape the strategies and market positioning of key industry players. Moreover, the emergence of biosimilars and generic medications is contributing to competitive pricing and expanding access to diabetes treatments, further impacting market dynamics.

In January 2022, Novo Nordisk India developed an oral formulation of an anti-diabetic medicine that was previously only available as injections, claiming that the new drug can help adults with type 2 diabetes better regulate their insulin levels and weight.

In September 2019, Rybelsus (semaglutide) oral tablets were given authorization by the FDA (Food & Drug Administration) to help adult patients with type 2 diabetes better regulate their blood sugar levels in conjunction with diet and exercise. Rybelsus is the first non-injected glucagon-like peptide (GLP-1) receptor protein therapy licensed in the United States.

In May 2019, AstraZeneca gained FDA approval for the utilization of Qternmet as an oral adjunct drug to diet and exercise to enhance glycemic control in individuals with type 2 diabetes.

Summary of Key Findings

The prevalence of type 2 diabetes is expected to continue increasing globally, driven by factors such as unhealthy lifestyles and an aging population.
Market segmented by medications and therapies, blood glucose monitoring, end user, complications management, age group, and region.
Combination therapies are expected to exhibit strong growth, reflecting the trend toward using multiple medications for effective glycemic control.
Continuous glucose monitoring (CGM) systems dominate the market, offering real-time data for better glycemic control. The market also sees increasing interest in less invasive blood glucose monitoring techniques using lancets and lancing devices.
Hospital end-users play a major role in diabetes management, particularly in handling acute complications and providing specialized care.
Diabetic neuropathy is the leading complications management category, reflecting the high prevalence of neuropathic symptoms.
The adult segment continues to dominate due to the majority of type 2 diabetes cases occurring in this age group.
Healthcare systems globally face challenges related to the rising costs of diabetes management, including medications and monitoring devices.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Future Outlook

Continuous glucose monitoring (CGM) systems and insulin delivery devices have seen significant technological advancements, enhancing the management of diabetes.
Various governments are launching public health campaigns and policies aimed at preventing and managing diabetes, including sugar taxation and education programs.
There is an increasing recognition of the association between type 2 diabetes and other health conditions, such as cardiovascular diseases, leading to a more comprehensive approach to diabetes care.
Healthcare providers are increasingly adopting collaborative care models involving multidisciplinary teams to address the various aspects of type 2 diabetes management, including nutrition, mental health, and lifestyle.

Segmentation

By Medications and Therapies
- Oral Antidiabetic Drugs (OADs)
- Insulin Therapy
- GLP-1 Receptor Agonists
- Combination Therapies
- Non-Pharmacological Interventions
- Insulin Delivery Devices
- Insulin Pens
- Insulin Syringes
- Insulin Pumps
- Insulin Jet Injectors
By Blood Glucose Monitoring
- Blood Glucose Meters
- Continuous Glucose Monitoring (CGM) Systems
- Lancets and Lancing Devices
By End User
- Hospitals
- Clinics and Specialty Centers
- Retail Pharmacies
- Home Use
By Complications Management
- Diabetic Neuropathy
- Diabetic Nephropathy
- Diabetic Retinopathy
- Cardiovascular Complications
By Age Group
- Pediatric
- Adult
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

In the type 2 diabetes market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for type 2 diabetes market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Type 2 Diabetes Market

2.1.1. Global Type 2 Diabetes Market, By Medications and Therapies

2.1.2. Global Type 2 Diabetes Market, By Blood Glucose Monitoring

2.1.3. Global Type 2 Diabetes Market, By End User

2.1.4. Global Type 2 Diabetes Market, By Complications Management

2.1.5. Global Type 2 Diabetes Market, By Age Group

2.1.6. Global Type 2 Diabetes Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Type 2 Diabetes Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Type 2 Diabetes Market Drivers

3.2.2. Type 2 Diabetes Market Restraints

3.2.3. Type 2 Diabetes Market Opportunities

3.2.4. Major Type 2 Diabetes Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Medications and Therapies

3.5.2. Blood Glucose Monitoring

3.5.3. End User

3.5.4. Complications Management

3.5.5. Age Group

3.5.6. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Type 2 Diabetes Market: Company Market Share, Value 2022

4.1.2. Global Type 2 Diabetes Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Type 2 Diabetes Market: Top 3 Company Market Share, Value 2022

4.2. Global Type 2 Diabetes Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Type 2 Diabetes Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Type 2 Diabetes Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Type 2 Diabetes Market, By Medications and Therapies

8.1. Global Type 2 Diabetes Market Overview, by Medications and Therapies

8.1.1. Global Type 2 Diabetes Market Revenue Share, By Medications and Therapies, 2022 Vs 2030 (in %)

8.2. Oral Antidiabetic Drugs (OADs)

8.2.1. Global Type 2 Diabetes Market, By Oral Antidiabetic Drugs (OADs), By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Oral Antidiabetic Drugs (OADs)

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Insulin Therapy

8.3.1. Global Type 2 Diabetes Market, By Insulin Therapy, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Insulin Therapy

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. GLP-1 Receptor Agonists

8.4.1. Global Type 2 Diabetes Market, By GLP-1 Receptor Agonists, By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for GLP-1 Receptor Agonists

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Combination Therapies

8.5.1. Global Type 2 Diabetes Market, By Combination Therapies, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Combination Therapies

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Non-Pharmacological Interventions

8.6.1. Global Type 2 Diabetes Market, By Non-Pharmacological Interventions, By Region, 2017-2030 (US$ Mn)

8.6.2. Market Dynamics for Non-Pharmacological Interventions

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

8.7. Insulin Delivery Devices

8.7.1. Global Type 2 Diabetes Market, By Insulin Delivery Devices, By Region, 2017-2030 (US$ Mn)

8.7.2. Market Dynamics for Insulin Delivery Devices

8.7.2.1. Drivers

8.7.2.2. Restraints

8.7.2.3. Opportunities

8.7.2.4. Trends

8.8. Insulin Pens

8.8.1. Global Type 2 Diabetes Market, By Insulin Pens, By Region, 2017-2030 (US$ Mn)

8.8.2. Market Dynamics for Insulin Pens

8.8.2.1. Drivers

8.8.2.2. Restraints

8.8.2.3. Opportunities

8.8.2.4. Trends

8.9. Insulin Syringes

8.9.1. Global Type 2 Diabetes Market, By Insulin Syringes, By Region, 2017-2030 (US$ Mn)

8.9.2. Market Dynamics for Insulin Syringes

8.9.2.1. Drivers

8.9.2.2. Restraints

8.9.2.3. Opportunities

8.9.2.4. Trends

8.10. Insulin Pumps

8.10.1. Global Type 2 Diabetes Market, By Insulin Pumps, By Region, 2017-2030 (US$ Mn)

8.10.2. Market Dynamics for Insulin Pumps

8.10.2.1. Drivers

8.10.2.2. Restraints

8.10.2.3. Opportunities

8.10.2.4. Trends

8.11. Insulin Jet Injectors

8.11.1. Global Type 2 Diabetes Market, By Insulin Jet Injectors, By Region, 2017-2030 (US$ Mn)

8.11.2. Market Dynamics for Insulin Jet Injectors

8.11.2.1. Drivers

8.11.2.2. Restraints

8.11.2.3. Opportunities

8.11.2.4. Trends

9. Global Type 2 Diabetes Market, By Blood Glucose Monitoring

9.1. Global Type 2 Diabetes Market Overview, by Blood Glucose Monitoring

9.1.1. Global Type 2 Diabetes Market Revenue Share, By Blood Glucose Monitoring, 2022 Vs 2030 (in %)

9.2. Blood Glucose Meters

9.2.1. Global Type 2 Diabetes Market, By Blood Glucose Meters, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Blood Glucose Meters

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Continuous Glucose Monitoring (CGM) Systems

9.3.1. Global Type 2 Diabetes Market, By Continuous Glucose Monitoring (CGM) Systems, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Continuous Glucose Monitoring (CGM) Systems

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Lancets and Lancing Devices

9.4.1. Global Type 2 Diabetes Market, By Lancets and Lancing Devices, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Lancets and Lancing Devices

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

10. Global Type 2 Diabetes Market, By End User

10.1. Global Type 2 Diabetes Market Overview, by End User

10.1.1. Global Type 2 Diabetes Market Revenue Share, By End User, 2022 Vs 2030 (in %)

10.2. Hospitals

10.2.1. Global Type 2 Diabetes Market, By Hospitals, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospitals

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Clinics and Specialty Centers

10.3.1. Global Type 2 Diabetes Market, By Clinics and Specialty Centers, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Clinics and Specialty Centers

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Retail Pharmacies

10.4.1. Global Type 2 Diabetes Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Retail Pharmacies

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

10.5. Home Use

10.5.1. Global Type 2 Diabetes Market, By Home Use, By Region, 2017-2030 (US$ Mn)

10.5.2. Market Dynamics for Home Use

10.5.2.1. Drivers

10.5.2.2. Restraints

10.5.2.3. Opportunities

10.5.2.4. Trends

11. Global Type 2 Diabetes Market, By Complications Management

11.1. Global Type 2 Diabetes Market Overview, by Complications Management

11.1.1. Global Type 2 Diabetes Market Revenue Share, By Complications Management, 2022 Vs 2030 (in %)

11.2. Diabetic Neuropathy

11.2.1. Global Type 2 Diabetes Market, By Diabetic Neuropathy, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Diabetic Neuropathy

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Diabetic Nephropathy

11.3.1. Global Type 2 Diabetes Market, By Diabetic Nephropathy, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Diabetic Nephropathy

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

11.4. Diabetic Retinopathy

11.4.1. Global Type 2 Diabetes Market, By Diabetic Retinopathy, By Region, 2017-2030 (US$ Mn)

11.4.2. Market Dynamics for Diabetic Retinopathy

11.4.2.1. Drivers

11.4.2.2. Restraints

11.4.2.3. Opportunities

11.4.2.4. Trends

11.5. Cardiovascular Complications

11.5.1. Global Type 2 Diabetes Market, By Cardiovascular Complications, By Region, 2017-2030 (US$ Mn)

11.5.2. Market Dynamics for Cardiovascular Complications

11.5.2.1. Drivers

11.5.2.2. Restraints

11.5.2.3. Opportunities

11.5.2.4. Trends

12. Global Type 2 Diabetes Market, By Age Group

12.1. Global Type 2 Diabetes Market Overview, by Age Group

12.1.1. Global Type 2 Diabetes Market Revenue Share, By Age Group, 2022 Vs 2030 (in %)

12.2. Pediatric

12.2.1. Global Type 2 Diabetes Market, By Pediatric, By Region, 2017-2030 (US$ Mn)

12.2.2. Market Dynamics for Pediatric

12.2.2.1. Drivers

12.2.2.2. Restraints

12.2.2.3. Opportunities

12.2.2.4. Trends

12.3. Adult

12.3.1. Global Type 2 Diabetes Market, By Adult, By Region, 2017-2030 (US$ Mn)

12.3.2. Market Dynamics for Adult

12.3.2.1. Drivers

12.3.2.2. Restraints

12.3.2.3. Opportunities

12.3.2.4. Trends

13. Global Type 2 Diabetes Market, By Region

13.1. Global Type 2 Diabetes Market Overview, by Region

13.1.1. Global Type 2 Diabetes Market, By Region, 2022 vs 2030 (in%)

13.2. Medications and Therapies

13.2.1. Global Type 2 Diabetes Market, By Medications and Therapies, 2017-2030 (US$ Mn)

13.3. Blood Glucose Monitoring

13.3.1. Global Type 2 Diabetes Market, By Blood Glucose Monitoring, 2017-2030 (US$ Mn)

13.4. End User

13.4.1. Global Type 2 Diabetes Market, By End User, 2017-2030 (US$ Mn)

13.5. Complications Management

13.5.1. Global Type 2 Diabetes Market, By Complications Management, 2017-2030 (US$ Mn)

13.6. Age Group

13.6.1. Global Type 2 Diabetes Market, By Age Group, 2017-2030 (US$ Mn)

14. North America Type 2 Diabetes Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. North America Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. North America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. North America Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. North America Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. North America Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

14.6.1. Overview

14.6.2. SRC Analysis

14.7. North America Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

14.7.1. North America Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

14.7.2. U.S.

14.7.3. Canada

14.7.4. Mexico

15. Europe Type 2 Diabetes Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Europe Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Europe Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Europe Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Europe Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Europe Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

15.6.1. Overview

15.6.2. SRC Analysis

15.7. Europe Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

15.7.1. Europe Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

15.7.2. UK

15.7.3. France

15.7.4. Germany

15.7.5. Italy

15.7.6. Spain

15.7.7. Benelux

15.7.8. Russia

15.7.9. Rest of Europe

16. Asia Pacific Type 2 Diabetes Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Asia Pacific Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Asia Pacific Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Asia Pacific Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Asia Pacific Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Asia Pacific Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

16.6.1. Overview

16.6.2. SRC Analysis

16.7. Asia Pacific Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

16.7.1. Asia Pacific Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

16.7.2. China

16.7.3. Japan

16.7.4. India

16.7.5. South Korea

16.7.6. South East Asia

16.7.7. Rest of Asia Pacific

17. Latin America Type 2 Diabetes Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Latin America Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Latin America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Latin America Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Latin America Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Latin America Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

17.6.1. Overview

17.6.2. SRC Analysis

17.7. Latin America Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

17.7.1. Latin America Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

17.7.2. Brazil

17.7.3. Argentina

17.7.4. Rest of Latin America

18. Middle East Type 2 Diabetes Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Middle East Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Middle East Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Middle East Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Middle East Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Middle East Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

18.6.1. Overview

18.6.2. SRC Analysis

18.7. Middle East Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

18.7.1. Middle East Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

18.7.2. UAE

18.7.3. Saudi Arabia

18.7.4. Rest of Middle East

19. Africa Type 2 Diabetes Market Analysis

19.1. Overview

19.1.1. Market Dynamics for North America

19.1.1.1. Drivers

19.1.1.2. Restraints

19.1.1.3. Opportunities

19.1.1.4. Trends

19.2. Africa Type 2 Diabetes Market, by Medications and Therapies, 2017-2030(US$ Mn)

19.2.1. Overview

19.2.2. SRC Analysis

19.3. Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2030(US$ Mn)

19.3.1. Overview

19.3.2. SRC Analysis

19.4. Africa Type 2 Diabetes Market, by End User, 2017-2030(US$ Mn)

19.4.1. Overview

19.4.2. SRC Analysis

19.5. Africa Type 2 Diabetes Market, by Complications Management, 2017-2030(US$ Mn)

19.5.1. Overview

19.5.2. SRC Analysis

19.6. Africa Type 2 Diabetes Market, by Age Group, 2017-2030(US$ Mn)

19.6.1. Overview

19.6.2. SRC Analysis

19.7. Africa Type 2 Diabetes Market, by Country, 2017-2030 (US$ Mn)

19.7.1. Middle East Type 2 Diabetes Market, by Country, 2022 Vs 2030 (in%)

19.7.2. South Africa

19.7.3. Egypt

19.7.4. Rest of Africa

20. Company Profiles

20.1. Amgen Inc

20.1.1. Company Overview

20.1.2. Products/Services Portfolio

20.1.3. Geographical Presence

20.1.4. SWOT Analysis

20.1.5. Financial Summary

20.1.5.1. Market Revenue and Net Profit (2019-2022)

20.1.5.2. Business Segment Revenue Analysis

20.1.5.3. Geographical Revenue Analysis

20.2. AstraZeneca PLC

20.3. Boehringer Ingelheim International GmbH

20.4. Daiichi Sankyo Co. Ltd

20.5. Eli Lilly and Co.

20.6. Merck & Co. Inc

20.7. Novartis AG

20.8. Novo Nordisk AS

20.9. Sanofi SA

20.10. Takeda Pharmaceutical Co. Ltd

20.11. Others

21. Research Methodology

21.1. Research Methodology

21.2. Phase I – Secondary Research

21.3. Phase II – Data Modelling

21.3.1. Company Share Analysis Model

21.3.2. Revenue Based Modelling

21.4. Phase III – Primary Research

21.5. Research Limitations

21.5.1. Assumptions

List of Figures

FIG. 1 Global Type 2 Diabetes Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Type 2 Diabetes Market Segmentation

FIG. 4 Global Type 2 Diabetes Market, by Medications and Therapies, 2022 (US$ Mn)

FIG. 5 Global Type 2 Diabetes Market, by Blood Glucose Monitoring, 2022 (US$ Mn)

FIG. 6 Global Type 2 Diabetes Market, by End User, 2022 (US$ Mn)

FIG. 7 Global Type 2 Diabetes Market, by Complications Management, 2022 (US$ Mn)

FIG. 8 Global Type 2 Diabetes Market, by Age Group, 2022 (US$ Mn)

FIG. 9 Global Type 2 Diabetes Market, by Geography, 2022 (US$ Mn)

FIG. 10 Attractive Investment Proposition, by Medications and Therapies, 2022

FIG. 11 Attractive Investment Proposition, by Blood Glucose Monitoring, 2022

FIG. 12 Attractive Investment Proposition, by End User, 2022

FIG. 13 Attractive Investment Proposition, by Complications Management, 2022

FIG. 14 Attractive Investment Proposition, by Age Group, 2022

FIG. 15 Attractive Investment Proposition, by Geography, 2022

FIG. 16 Global Market Share Analysis of Key Type 2 Diabetes Market Manufacturers, 2022

FIG. 17 Global Market Positioning of Key Type 2 Diabetes Market Manufacturers, 2022

FIG. 18 Global Type 2 Diabetes Market Value Contribution, By Medications and Therapies, 2022 & 2030 (Value %)

FIG. 19 Global Type 2 Diabetes Market, by Oral Antidiabetic Drugs (OADs), Value, 2017-2030 (US$ Mn)

FIG. 20 Global Type 2 Diabetes Market, by Insulin Therapy, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Type 2 Diabetes Market, by GLP-1 Receptor Agonists, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Type 2 Diabetes Market, by Combination Therapies, Value, 2017-2030 (US$ Mn)

FIG. 23 Global Type 2 Diabetes Market, by Non-Pharmacological Interventions, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Type 2 Diabetes Market, by Insulin Delivery Devices, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Type 2 Diabetes Market, by Insulin Pens, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Type 2 Diabetes Market, by Insulin Syringes, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Type 2 Diabetes Market, by Insulin Pumps, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Type 2 Diabetes Market, by Insulin Jet Injectors, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Type 2 Diabetes Market Value Contribution, By Blood Glucose Monitoring, 2022 & 2030 (Value %)

FIG. 30 Global Type 2 Diabetes Market, by Blood Glucose Meters, Value, 2017-2030 (US$ Mn)

FIG. 31 Global Type 2 Diabetes Market, by Continuous Glucose Monitoring (CGM) Systems, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Type 2 Diabetes Market, by Lancets and Lancing Devices, Value, 2017-2030 (US$ Mn)

FIG. 33 Global Type 2 Diabetes Market Value Contribution, By End User, 2022 & 2030 (Value %)

FIG. 34 Global Type 2 Diabetes Market, by Hospitals, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Type 2 Diabetes Market, by Clinics and Specialty Centers, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Type 2 Diabetes Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 37 Global Type 2 Diabetes Market, by Home Use, Value, 2017-2030 (US$ Mn)

FIG. 38 Global Type 2 Diabetes Market Value Contribution, By Complications Management, 2022 & 2030 (Value %)

FIG. 39 Global Type 2 Diabetes Market, by Diabetic Neuropathy, Value, 2017-2030 (US$ Mn)

FIG. 40 Global Type 2 Diabetes Market, by Diabetic Nephropathy, Value, 2017-2030 (US$ Mn)

FIG. 41 Global Type 2 Diabetes Market, by Diabetic Retinopathy, Value, 2017-2030 (US$ Mn)

FIG. 42 Global Type 2 Diabetes Market, by Cardiovascular Complications, Value, 2017-2030 (US$ Mn)

FIG. 43 Global Type 2 Diabetes Market Value Contribution, By Age Group, 2022 & 2030 (Value %)

FIG. 44 Global Type 2 Diabetes Market, by Pediatric, Value, 2017-2030 (US$ Mn)

FIG. 45 Global Type 2 Diabetes Market, by Adult, Value, 2017-2030 (US$ Mn)

FIG. 46 North America Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 47 U.S. Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 48 Canada Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 49 Mexico Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 50 Europe Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 51 Germany Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 52 France Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 53 U.K. Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 54 Italy Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 55 Spain Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 56 Benelux Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 57 Russia Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 58 Rest of Europe Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 59 Asia Pacific Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 60 China Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 61 Japan Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 62 India Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 63 South Korea Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 64 South-East Asia Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 65 Rest of Asia Pacific Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 66 Latin America Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 67 Brazil Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 68 Argentina Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 69 Rest of Latin America Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 70 Middle East Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 71 UAE Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 72 Saudi Arabia Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 73 Rest of Middle East Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 74 Africa Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 75 South Africa Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 76 Egypt Type 2 Diabetes Market, 2017-2030 (US$ Mn)

FIG. 77 Rest of Africa Type 2 Diabetes Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Type 2 Diabetes Market

TABLE 2 Global Type 2 Diabetes Market: Market Drivers Impact Analysis

TABLE 3 Global Type 2 Diabetes Market: Market Restraints Impact Analysis

TABLE 4 Global Type 2 Diabetes Market, by Competitive Benchmarking, 2022

TABLE 5 Global Type 2 Diabetes Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Type 2 Diabetes Market, by Key Strategies Analysis, 2022

TABLE 7 Global Type 2 Diabetes Market, by Oral Antidiabetic Drugs (OADs), By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Type 2 Diabetes Market, by Oral Antidiabetic Drugs (OADs), By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Type 2 Diabetes Market, by Insulin Therapy, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Type 2 Diabetes Market, by Insulin Therapy, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Type 2 Diabetes Market, by GLP-1 Receptor Agonists, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Type 2 Diabetes Market, by GLP-1 Receptor Agonists, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Type 2 Diabetes Market, by Combination Therapies, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Type 2 Diabetes Market, by Combination Therapies, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Type 2 Diabetes Market, by Non-Pharmacological Interventions, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Type 2 Diabetes Market, by Non-Pharmacological Interventions, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Type 2 Diabetes Market, by Insulin Delivery Devices, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Type 2 Diabetes Market, by Insulin Delivery Devices, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Type 2 Diabetes Market, by Insulin Pens, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Type 2 Diabetes Market, by Insulin Pens, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Type 2 Diabetes Market, by Insulin Syringes, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Type 2 Diabetes Market, by Insulin Syringes, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Type 2 Diabetes Market, by Insulin Pumps, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Type 2 Diabetes Market, by Insulin Pumps, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Type 2 Diabetes Market, by Insulin Jet Injectors, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Type 2 Diabetes Market, by Insulin Jet Injectors, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Type 2 Diabetes Market, by Blood Glucose Meters, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Type 2 Diabetes Market, by Blood Glucose Meters, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Type 2 Diabetes Market, by Continuous Glucose Monitoring (CGM) Systems, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Type 2 Diabetes Market, by Continuous Glucose Monitoring (CGM) Systems, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Type 2 Diabetes Market, by Lancets and Lancing Devices, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Type 2 Diabetes Market, by Lancets and Lancing Devices, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Type 2 Diabetes Market, by Hospitals, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Type 2 Diabetes Market, by Hospitals, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Type 2 Diabetes Market, by Clinics and Specialty Centers, By Region, 2017-2022 (US$ Mn)

TABLE 36 Global Type 2 Diabetes Market, by Clinics and Specialty Centers, By Region, 2023-2030 (US$ Mn)

TABLE 37 Global Type 2 Diabetes Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 38 Global Type 2 Diabetes Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 39 Global Type 2 Diabetes Market, by Home Use, By Region, 2017-2022 (US$ Mn)

TABLE 40 Global Type 2 Diabetes Market, by Home Use, By Region, 2023-2030 (US$ Mn)

TABLE 41 Global Type 2 Diabetes Market, by Diabetic Neuropathy, By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Type 2 Diabetes Market, by Diabetic Neuropathy, By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Type 2 Diabetes Market, by Diabetic Nephropathy, By Region, 2017-2022 (US$ Mn)

TABLE 44 Global Type 2 Diabetes Market, by Diabetic Nephropathy, By Region, 2023-2030 (US$ Mn)

TABLE 45 Global Type 2 Diabetes Market, by Diabetic Retinopathy, By Region, 2017-2022 (US$ Mn)

TABLE 46 Global Type 2 Diabetes Market, by Diabetic Retinopathy, By Region, 2023-2030 (US$ Mn)

TABLE 47 Global Type 2 Diabetes Market, by Cardiovascular Complications, By Region, 2017-2022 (US$ Mn)

TABLE 48 Global Type 2 Diabetes Market, by Cardiovascular Complications, By Region, 2023-2030 (US$ Mn)

TABLE 49 Global Type 2 Diabetes Market, by Pediatric, By Region, 2017-2022 (US$ Mn)

TABLE 50 Global Type 2 Diabetes Market, by Pediatric, By Region, 2023-2030 (US$ Mn)

TABLE 51 Global Type 2 Diabetes Market, by Adult, By Region, 2017-2022 (US$ Mn)

TABLE 52 Global Type 2 Diabetes Market, by Adult, By Region, 2023-2030 (US$ Mn)

TABLE 53 Global Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 54 Global Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 55 Global Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 56 Global Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 57 Global Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 58 Global Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 59 Global Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 60 Global Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 61 Global Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 62 Global Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 63 Global Type 2 Diabetes Market, by Region, 2017-2022 (US$ Mn)

TABLE 64 Global Type 2 Diabetes Market, by Region, 2023-2030 (US$ Mn)

TABLE 65 North America Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 66 North America Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 67 North America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 68 North America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 69 North America Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 70 North America Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 71 North America Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 72 North America Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 73 North America Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 74 North America Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 75 North America Type 2 Diabetes Market, by Country, 2017-2022 (US$ Mn)

TABLE 76 North America Type 2 Diabetes Market, by Country, 2023-2030 (US$ Mn)

TABLE 77 United States Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 78 United States Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 79 United States Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 80 United States Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 81 United States Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 82 United States Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 83 United States Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 84 United States Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 85 United States Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 86 United States Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 87 Canada Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 88 Canada Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 89 Canada Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 90 Canada Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 91 Canada Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 92 Canada Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 93 Canada Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 94 Canada Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 95 Canada Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 96 Canada Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 97 Mexico Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 98 Mexico Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 99 Mexico Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 100 Mexico Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 101 Mexico Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 102 Mexico Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 103 Mexico Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 104 Mexico Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 105 Mexico Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 106 Mexico Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 107 Europe Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 108 Europe Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 109 Europe Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 110 Europe Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 111 Europe Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 112 Europe Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 113 Europe Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 114 Europe Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 115 Europe Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 116 Europe Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 117 Europe Type 2 Diabetes Market, by Country, 2017-2022 (US$ Mn)

TABLE 118 Europe Type 2 Diabetes Market, by Country, 2023-2030 (US$ Mn)

TABLE 119 Germany Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 120 Germany Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 121 Germany Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 122 Germany Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 123 Germany Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 124 Germany Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 125 Germany Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 126 Germany Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 127 Germany Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 128 Germany Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 129 France Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 130 France Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 131 France Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 132 France Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 133 France Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 134 France Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 135 France Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 136 France Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 137 France Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 138 France Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 139 United Kingdom Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 140 United Kingdom Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 141 United Kingdom Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 142 United Kingdom Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 143 United Kingdom Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 144 United Kingdom Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 145 United Kingdom Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 146 United Kingdom Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 147 United Kingdom Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 148 United Kingdom Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 149 Italy Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 150 Italy Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 151 Italy Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 152 Italy Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 153 Italy Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 154 Italy Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 155 Italy Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 156 Italy Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 157 Italy Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 158 Italy Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 159 Spain Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 160 Spain Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 161 Spain Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 162 Spain Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 163 Spain Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 164 Spain Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 165 Spain Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 166 Spain Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 167 Spain Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 168 Spain Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 169 Benelux Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 170 Benelux Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 171 Benelux Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 172 Benelux Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 173 Benelux Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 174 Benelux Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 175 Benelux Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 176 Benelux Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 177 Benelux Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 178 Benelux Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 179 Russia Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 180 Russia Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 181 Russia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 182 Russia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 183 Russia Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 184 Russia Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 185 Russia Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 186 Russia Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 187 Russia Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 188 Russia Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 189 Rest of Europe Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 190 Rest of Europe Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 191 Rest of Europe Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 192 Rest of Europe Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 193 Rest of Europe Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 194 Rest of Europe Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 195 Rest of Europe Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 196 Rest of Europe Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 197 Rest of Europe Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 198 Rest of Europe Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 199 Asia Pacific Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 200 Asia Pacific Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 201 Asia Pacific Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 202 Asia Pacific Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 203 Asia Pacific Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 204 Asia Pacific Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 205 Asia Pacific Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 206 Asia Pacific Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 207 Asia Pacific Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 208 Asia Pacific Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 209 China Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 210 China Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 211 China Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 212 China Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 213 China Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 214 China Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 215 China Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 216 China Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 217 China Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 218 China Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 219 Japan Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 220 Japan Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 221 Japan Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 222 Japan Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 223 Japan Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 224 Japan Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 225 Japan Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 226 Japan Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 227 Japan Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 228 Japan Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 229 India Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 230 India Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 231 India Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 232 India Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 233 India Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 234 India Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 235 India Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 236 India Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 237 India Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 238 India Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 239 South Korea Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 240 South Korea Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 241 South Korea Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 242 South Korea Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 243 South Korea Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 244 South Korea Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 245 South Korea Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 246 South Korea Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 247 South Korea Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 248 South Korea Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 249 South-East Asia Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 250 South-East Asia Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 251 South-East Asia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 252 South-East Asia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 253 South-East Asia Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 254 South-East Asia Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 255 South-East Asia Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 256 South-East Asia Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 257 South-East Asia Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 258 South-East Asia Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 259 Rest of Asia Pacific Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 260 Rest of Asia Pacific Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 261 Rest of Asia Pacific Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 262 Rest of Asia Pacific Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 263 Rest of Asia Pacific Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 264 Rest of Asia Pacific Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 265 Rest of Asia Pacific Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 266 Rest of Asia Pacific Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 267 Rest of Asia Pacific Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 268 Rest of Asia Pacific Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 269 Latin America Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 270 Latin America Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 271 Latin America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 272 Latin America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 273 Latin America Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 274 Latin America Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 275 Latin America Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 276 Latin America Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 277 Latin America Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 278 Latin America Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 279 Brazil Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 280 Brazil Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 281 Brazil Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 282 Brazil Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 283 Brazil Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 284 Brazil Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 285 Brazil Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 286 Brazil Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 287 Brazil Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 288 Brazil Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 289 Argentina Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 290 Argentina Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 291 Argentina Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 292 Argentina Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 293 Argentina Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 294 Argentina Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 295 Argentina Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 296 Argentina Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 297 Argentina Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 298 Argentina Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 299 Rest of Latin America Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 300 Rest of Latin America Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 301 Rest of Latin America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 302 Rest of Latin America Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 303 Rest of Latin America Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 304 Rest of Latin America Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 305 Rest of Latin America Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 306 Rest of Latin America Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 307 Rest of Latin America Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 308 Rest of Latin America Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 309 Middle East Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 310 Middle East Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 311 Middle East Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 312 Middle East Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 313 Middle East Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 314 Middle East Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 315 Middle East Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 316 Middle East Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 317 Middle East Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 318 Middle East Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 319 UAE Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 320 UAE Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 321 UAE Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 322 UAE Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 323 UAE Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 324 UAE Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 325 UAE Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 326 UAE Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 327 UAE Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 328 UAE Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 329 Saudi Arabia Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 330 Saudi Arabia Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 331 Saudi Arabia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 332 Saudi Arabia Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 333 Saudi Arabia Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 334 Saudi Arabia Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 335 Saudi Arabia Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 336 Saudi Arabia Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 337 Saudi Arabia Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 338 Saudi Arabia Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 339 Rest of Middle East Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 340 Rest of Middle East Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 341 Rest of Middle East Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 342 Rest of Middle East Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 343 Rest of Middle East Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 344 Rest of Middle East Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 345 Rest of Middle East Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 346 Rest of Middle East Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 347 Rest of Middle East Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 348 Rest of Middle East Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 349 Africa Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 350 Africa Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 351 Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 352 Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 353 Africa Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 354 Africa Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 355 Africa Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 356 Africa Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 357 Africa Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 358 Africa Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 359 South Africa Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 360 South Africa Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 361 South Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 362 South Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 363 South Africa Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 364 South Africa Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 365 South Africa Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 366 South Africa Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 367 South Africa Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 368 South Africa Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 369 Egypt Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 370 Egypt Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 371 Egypt Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 372 Egypt Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 373 Egypt Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 374 Egypt Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 375 Egypt Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 376 Egypt Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 377 Egypt Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 378 Egypt Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

TABLE 379 Rest of Africa Type 2 Diabetes Market, by Medications and Therapies, 2017-2022 (US$ Mn)

TABLE 380 Rest of Africa Type 2 Diabetes Market, by Medications and Therapies, 2023-2030 (US$ Mn)

TABLE 381 Rest of Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2017-2022 (US$ Mn)

TABLE 382 Rest of Africa Type 2 Diabetes Market, by Blood Glucose Monitoring, 2023-2030 (US$ Mn)

TABLE 383 Rest of Africa Type 2 Diabetes Market, by End User, 2017-2022 (US$ Mn)

TABLE 384 Rest of Africa Type 2 Diabetes Market, by End User, 2023-2030 (US$ Mn)

TABLE 385 Rest of Africa Type 2 Diabetes Market, by Complications Management, 2017-2022 (US$ Mn)

TABLE 386 Rest of Africa Type 2 Diabetes Market, by Complications Management, 2023-2030 (US$ Mn)

TABLE 387 Rest of Africa Type 2 Diabetes Market, by Age Group, 2017-2022 (US$ Mn)

TABLE 388 Rest of Africa Type 2 Diabetes Market, by Age Group, 2023-2030 (US$ Mn)

Frequently asked questions

What is the current size of the global type 2 diabetes market?

The global type 2 diabetes market was valued at USD 29945.8 Million in 2022.

What is the expected growth rate of the type 2 diabetes market between 2023 and 2030?

The type 2 diabetes market is expected to grow at a CAGR of 8.8% between 2023 and 2030, reaching USD 58798.6 Million in 2030.

Which segment is leading the market share in terms of medications and therapies?

Insulin therapy is the leading segment by medications and therapies, holding over 20% share in value in 2022.

Which blood glucose monitoring segment governs the demand for type 2 diabetes in the world?

The continuous glucose monitoring (CGM) systems segment governs the global demand for type 2 diabetes, holding a massive share of over 40% in 2022.

Which complications management segment will post the highest CAGR in the forecast period?

The diabetic nephropathy segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the type 2 diabetes industry?

With more than one-third of the market in 2022, North America is driving the expansion of the type 2 diabetes industry.

Who are the major players in the global type 2 diabetes market?

The top players include Boehringer Ingelheim International GmbH, AstraZeneca PLC, Daiichi Sankyo Co. Ltd, Amgen Inc, Eli Lilly & Co., Novartis AG, Merck & Co. Inc, Sanofi SA, Novo Nordisk AS, Takeda Pharmaceutical Co. Ltd, and Others.

What are the major market drivers of the type 2 diabetes industry?

The major market drivers of the type 2 diabetes industry include rising diabetes prevalence, pharmaceutical and technological innovations, and increasing awareness and access to healthcare.

What are the major market restraints of the type 2 diabetes industry?

The major market restraints of the type 2 diabetes industry include high healthcare costs and healthcare disparities, which limit access to care for some populations.

What are the major market opportunities of the type 2 diabetes industry?

The major market opportunities of the type 2 diabetes industry include advancements in personalized medicine and precision diabetology, as well as the growth of digital health and telemedicine solutions for more effective and patient-centered care.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –